Skip to main content
Article thumbnail
Location of Repository

Liver Stem Cells and TGF-β in Hepatic Carcinogenesis

By Rupen Amin and Lopa Mishra


Hepatocellular carcinoma is the fifth most common malignancy worldwide. Recent trends indicate a rising incidence in the United States, with a 5-year survival rate of less than 5%. New therapeutics targeting advanced-stage hepatocellular carcinoma, such as sorafenib, have marginally improved the median overall survival by 3 months. There is an urgent need for new targeted agents that are associated with minimal local and systemic toxicities. Up to 40% of hepatocellular carcinomas are clonal, potentially arising from stem cells and increased activation of multiple pathways including IL-6/STAT3, WNT, CDK4, and hedgehog, as well as loss of response to the transforming growth factor-beta (TGF-β) signaling pathway. Our hypothesis has been that these “cancer stem cells” or cancer sustaining cells may prove to be strong genetic and therapeutic targets. Modulating stem cell renewal factors such as STAT3, NANOG, and OCT4 may reduce hepatocellular carcinoma formation. These points are discussed in detail in this review

Topics: Feature Article
Publisher: International Society of Gastrointestinal Oncology
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.